Johnson & Johnson (JNJ) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Johnson & Johnson (JNJ) insider buying and selling: 1 purchase, 19 sales
88 Form 4 Table I transactions filed with the SEC by Johnson & Johnson insiders between 2025-08-25 and 2026-09-04 (15-month history): 1 open-market purchase and 19 sales, plus 68 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $32.2M by Duato Joaquin on 2026-08-13.
Johnson & Johnson insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Johnson & Johnson insiders filed 1 purchase worth $258k and 16 sales worth $150.7M on the open market. The net balance is on the sell side: $150.4M more sold than bought.
The biggest buyer was Morikis John G (Director): $258k in 1 purchase, the only buyer. The biggest seller was Duato Joaquin (CEO and Chairman of the Board): $66.8M in 3 sales, out of 10 different sellers.
The largest trade of the period was a sale of $32.2M on Aug 13, 2026, by Duato Joaquin (CEO and Chairman of the Board). Form 4 on sec.gov (0000200406-26-000173).
None of the 16 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 0 purchases and 5 sales, against 0 and 2 in the three before. The latest purchase is from Nov 26, 2025; the latest sale from Sep 2, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Johnson & Johnson has more sales than 42 of the other 58, ranks 8 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, Johnson & Johnson included.
The 20 most important trades
The only open-market purchase first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 88 JNJ trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-11-26 | 2025-12-01 | Morikis John G | Director | $258k | P — Open-market purchase | SEC |
| 2026-08-13 | 2026-08-14 | Duato Joaquin | CEO and Chairman of the Board | $32.2M | S — Open-market sale | SEC |
| 2025-08-22 | 2025-08-25 | Duato Joaquin | CEO and Chairman of the Board | $22.5M | S — Open-market saleForm 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $178.985 to $179.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-01-26 | 2026-01-28 | Duato Joaquin | CEO and Chairman of the Board | $22.1M | S — Open-market sale Indirect holding, through: By spouse 2 Form 4 footnotesF1 This transaction was executed in multiple trades at prices ranging from $220.39 to $221.376. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $221.38 to $221.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-17 | 2026-02-18 | Wolk Joseph J | Exec VP, CFO | $21.8M | S — Open-market sale4 Form 4 footnotesF7 This transaction was executed in multiple trades at prices ranging from $242.94 to $243.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F8 This transaction was executed in multiple trades at prices ranging from $242.85 to $242.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F9 This transaction was executed in multiple trades at prices ranging from $242.71 to $242.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 This transaction was executed in multiple trades at prices ranging from $242.59 to $242.815. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-17 | 2026-02-18 | Reed John C | EVP, Innovative Medicine, R&D | $13.1M | S — Open-market sale | SEC |
| 2026-08-05 | 2026-08-07 | Duato Joaquin | CEO and Chairman of the Board | $12.5M | S — Open-market sale2 Form 4 footnotesF1 This transaction was executed in multiple trades at prices ranging from $257.53 to $258.505. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple trades at prices ranging from $258.535 to $259.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-13 | 2026-02-18 | Swanson James D. | EVP, CIO | $10.1M | S — Open-market sale2 Form 4 footnotesF5 This transaction was executed in multiple trades at prices ranging from $243.74 to $243.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 This transaction was executed in multiple trades at prices ranging from $243.64 to $243.895. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-09-04 | 2025-09-05 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | $10.0M | S — Open-market saleForm 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $177.715 to $177.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-09-02 | 2026-09-04 | Schmid Timothy | EVP, WW Chair, MedTech | $9.2M | S — Open-market sale | SEC |
| 2026-07-20 | 2026-07-21 | Broadhurst Vanessa | EVP, Global Corp Affairs | $5.8M | S — Open-market saleForm 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $251.09 to $251.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-18 | 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | $5.5M | S — Open-market saleForm 4 footnoteF7 This transaction was executed in multiple trades at prices ranging from $244.20 to $244.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-17 | 2026-02-18 | Swanson James D. | EVP, CIO | $5.0M | S — Open-market saleForm 4 footnoteF9 This transaction was executed in multiple trades at prices ranging from $242.69 to $242.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2025-10-17 | 2025-10-20 | Reed John C | EVP, Innovative Medicine, R&D | $4.2M | S — Open-market saleForm 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-08-06 | 2026-08-07 | Forminard Elizabeth | EVP, Chief Legal Officer | $4.1M | S — Open-market sale | SEC |
| 2026-08-17 | 2026-08-18 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | $4.0M | S — Open-market saleForm 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-06-11 | 2026-06-12 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | $2.4M | S — Open-market saleForm 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $240.14 to $240.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-17 | 2026-02-18 | Broadhurst Vanessa | EVP, Global Corp Affairs | $1.5M | S — Open-market saleForm 4 footnoteF7 This transaction was executed in multiple trades at prices ranging from $243.39 to $243.41. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-02-27 | 2026-03-03 | Decker Robert J | VP Corporate Controller | $1.0M | S — Open-market sale | SEC |
| 2026-02-20 | 2026-02-23 | Schmid Timothy | EVP, WW Chair, MedTech | $325k | S — Open-market sale | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Aug 25, 2025 and Sep 4, 2026, Johnson & Johnson open-market activity adds up to 1 purchase worth $258k and 19 sales worth $187.4M. The net balance is $187.2M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Johnson & Johnson's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| M | Option exercise | 41 | $86.6M |
| F | Tax withholding (shares surrendered for taxes) | 27 | $40.0M |
| S | Open-market sale | 19 | $187.4M |
| P | Open-market purchase | 1 | $258k |
| Total | Everything filed in the period | 88 | $314.3M |
21 of the 88 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 12 distinct people or entities have filed Johnson & Johnson transactions: 1 bought on the open market and 10 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 10 who sold on the open market (19 sales in all), the three biggest sellers account for $128.4M of the $187.4M: 69% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Duato Joaquin | CEO and Chairman of the Board | 10 | — | $89.4M (4) | 2026-08-14 |
| Wolk Joseph J | Exec VP, CFO | 6 | — | $21.8M (1) | 2026-02-18 |
| Reed John C | EVP, Innovative Medicine, R&D | 8 | — | $17.3M (2) | 2026-05-04 |
| Swanson James D. | EVP, CIO | 7 | — | $15.1M (2) | 2026-02-18 |
| Schmid Timothy | EVP, WW Chair, MedTech | 11 | — | $15.1M (3) | 2026-09-04 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 8 | — | $14.0M (2) | 2026-08-18 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | 7 | — | $7.3M (2) | 2026-07-21 |
| Forminard Elizabeth | EVP, Chief Legal Officer | 10 | — | $4.1M (1) | 2026-08-07 |
Shown here are the 8 who moved the most money, out of 12. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Feb 2026: 0 purchases and 8 sales, worth $58.4M. 5 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $22.5M |
| Sep 2025 | 0 | $0 | 1 | $10.0M |
| Oct 2025 | 0 | $0 | 1 | $4.2M |
| Nov 2025 | 1 | $258k | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 1 | $22.1M |
| Feb 2026 | 0 | $0 | 8 | $58.4M |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 1 | $2.4M |
| Jul 2026 | 0 | $0 | 1 | $5.8M |
| Aug 2026 | 0 | $0 | 4 | $52.8M |
| Sep 2026 | 0 | $0 | 1 | $9.2M |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Johnson & Johnson (JNJ) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 19 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Johnson & Johnson's single open-market purchase (code P) is the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Sep 4, 2026, and a Form 4 arrives up to two business days after the trade.
13 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.